Yahoo Finance Analysts Have Just Cut Their Kaleido Biosciences, Inc. (NASDAQ:KLDO) Revenue Estimates By 20%
The latest analyst coverage could presage a bad day for Kaleido Biosciences, Inc. (NASDAQ:KLDO), with the analysts making across-the-board cuts to their statutory estimates that might leave shareholders a little shell-shocked. This report focused on revenue estimates, and it looks as though the consensus view of the business has become substantially more conservative.
After the downgrade, the five analysts covering Kaleido Biosciences are now predicting revenues of US$14m in 2020. If met, this would reflect a major improvement in sales compared to the last 12 months. Prior to the latest estimates, the analysts were forecasting revenues of US$18m in 2020. The consensus view seems to have become more pessimistic on Kaleido Biosciences, noting the sizeable cut to revenue estimates in this update.
View our latest analysis for Kaleido Biosciences
The Bottom Line
The clear low-light was that analysts slashing their revenue forecasts for Kaleido Biosciences this year. Given the stark change in sentiment, we'd understand if investors became more cautious on Kaleido Biosciences after today.
There might be good reason for analyst bearishness towards Kaleido Biosciences, like dilutive stock issuance over the past year. For more information, you can click here to discover this and the 3 other risks we've identified.
Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying.
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.
